Trial · NCT06275763
Optimal Medical Treatment of Difficult-to-treat Hypertension
NCT06275763, Phase 4, Unknown, National Institute of Cardiology, Warsaw, Poland
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Optimal Medical Treatment of Difficult-to-treat Hypertension. Trials, record NCT06275763. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06275763
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimal Medical Treatment of Difficult-to-treat Hypertension
- NCT number
- NCT06275763
- Status
- Unknown
- Phases
- Phase 4
- Enrollment
- 2,500 participants, estimated
- Lead sponsor
- National Institute of Cardiology, Warsaw, Poland
- Conditions
- Hypertension
- Interventions
- Phase C: Eplerenone, Phase C: Spironolactone, Phase C: Torasemide, Phase B: Triplixam / Elestar HCT, Phase A: Confirmation of uncontrolled hypertension
- First posted
- 2024-02-23
- Last updated
- 2024-02-23
Source ClinicalTrials.gov
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patients with uncontrolled BP on ABPM | First week of the patients' participation in the study | Percentage of patients with uncontrolled BP confirmed on ABPM (24h mean, SBP ≥125 mm Hg or DBP ≥80 mm Hg) |
| Primary | Patients with controlled BP after 12 weeks on triple SPC | Next 12 weeks of the patients' participation in the study | Percentage of patients with controlled BP after 12 weeks of treatment with triple SPC, confirmed on ABPM (24h mean, SBP \<125 mm Hg and DBP \<80 mm Hg) - as the efficacy of the treatment strategy (switching ineffective treatment to triple SPC) - the whole group and P+I+A and E+H+A groups separetly. |
| Primary | Systolic BP reduction on 4th antihypertensive drug | Last 24 weeks of the patients' participation in the study | Magnitude of reduction of SBP on ABPM (24h mean) after 12 weeks of treatment - comparison of eplerenone vs spironolactone and torasemide vs spironolactone. |
| Secondary | Percentage of patients with BP controlled confirmed by HBPM | First week of the patients' participation in the study | Percentage of patients with BP controlled confirmed by HBPM (mean over the period of 6 days, SBP ≥130 mm Hg or DBP ≥80 mm Hg) |
| Secondary | Consistency of the rate of uncontrolled BP | First week of the patients' participation in the study | Consistency of the rate of uncontrolled BP between ABPM and HBPM |
| Secondary | Percentage of patients with controlled BP after 12 weeks of treatment, confirmed by OBPM | Next 12 weeks of the patients' participation in the study | Percentage of patients with controlled BP after 12 weeks of treatment, confirmed by OBPM (SBP \<130 mm Hg and DBP \<80 mm Hg). |
| Secondary | Percentage of patients with controlled BP after 12 weeks of treatment, confirmed by HBPM | Next 12 weeks of the patients' participation in the study | Percentage of patients with controlled BP after 12 weeks of treatment, confirmed by HBPM (mean over 6 days, SBP \<130 mm Hg and DBP \<80 mm Hg). |
| Secondary | Percentage of patients with controlled BP after 12 weeks of treatment, confirmed by ABPM | Next 12 weeks of the patients' participation in the study | Percentage of patients with controlled BP after 12 weeks of treatment, confirmed by ABPM in daytime (SBP \<135 mm Hg and DBP \<85 mm Hg) and nighttime (SBP \<120 mm Hg and DBP \<70 mm Hg) reading. |
| Secondary | Percentage of patients requiring an increase in the dose | Next 12 weeks of the patients' participation in the study | Percentage of patients requiring an increase in the dose of drugs used in the whole group and in the patients treated with P+I+A and O+H+A separately. |
| Secondary | Consistency of the rate of uncontrolled BP | Next 12 weeks of the patients' participation in the study | Consistency of the rate of uncontrolled BP between ABPM, HBPM and OBPM. |
1 to 10 of 29Source ClinicalTrials.gov
See all 29 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06275763
GET https://conductscience.org/api/trials/v1/NCT06275763/registered?page=2